Open for inclusion

An open-label, multicenter, dose-escalation phase 1b study to investigate the safety, pharmacokinetics, phamacodynamics, and therapeutic activity of RO7009789 (CD40 agonist) in combination with MPDL3280A (anti-PD-L1) in patients with locally advancedand/o

Cancer type: Solide tumores

Phase: I

Principal Investigator: Lassen Ulrik

Country: DK

Keywords: Denmark, Rigshospitalet

Status: Open for inclusion

Link to